{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 42,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "context",
  "function": "establish_context",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a sidebar 'AT A GLANCE' to summarize key program attributes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/27",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.878,
        "w": 0.286,
        "x": 0.714,
        "y": 0
      },
      "kind": "callout",
      "text": "AT A GLANCE\n\nMechanism of Action:\nROS1-selective tyrosine kinase inhibitor\n\nStage of Development:\nGlobal Phase 2 with registrational intent\n\nInitial Development Indication:\nROS1-positive NSCLC\n\nFDA Designations:\nOrphan Drug Designation",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0e2f509-f199-4f04-b536-b88834930d9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.08,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "A brain-penetrant, selective inhibitor of ROS1 and ROS1 resistance mutations with the potential to minimize TRK-related CNS adverse events while providing CNS antitumor activity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bab569a-a99e-4afa-b992-ce491d54e90a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.08,
        "y": 0.38
      },
      "kind": "title",
      "text": "NVL-520 for ROS1+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67e80f6a-c967-4bb9-aa37-96aea8b2e0e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}